Why the study?
Does the timing of immunotherapy administration in severe sepsis and septic shock align with peak circulatory biomarker activity?
Population
Patients with severe sepsis and septic shock, alongside animal and human research models
Design
Review
Follow-up
72 hours (for biomarker observation)
Authors
Loading...
May explain prior sepsis immunotherapy trial failures; hypothesis-generating for earlier enrollment in prospective studies.
Does the timing of immunotherapy administration in severe sepsis and septic shock align with peak circulatory biomarker activity?
The failure of previous immunotherapy trials in sepsis may be due to delayed administration after the optimal window of peak biomarker activity, suggesting a need to recalibrate enrollment timing.
Rivers et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: